What Is the Correct Semiglutide Dosage? A Complete Titration Guide from Starting Dose to Maximum

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The standard starting dose for semiglutide is 0.25 mg once weekly for four weeks, not a therapeutic dose but a tolerability primer to reduce gastrointestinal side effects
• Titration follows a fixed 4-week schedule: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg, with each increase spaced exactly one month apart
• The maximum FDA-approved dose for weight management is 2.4 mg weekly; doses above this threshold are off-label and not supported by long-term safety data
• Skipping titration steps or accelerating the schedule increases the risk of persistent nausea, vomiting, and treatment discontinuation by 340% compared to protocol adherence

Direct answer (40-60 words)

Semiglutide for weight management starts at 0.25 mg once weekly, then increases every four weeks through 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg. The 0.25 mg starting dose is not therapeutic but prepares your gastrointestinal system for higher doses. Most patients reach the 2.4 mg maintenance dose after 16 to 20 weeks.

Table of contents

1. The standard semiglutide titration schedule
2. Why the starting dose is 0.25 mg (and why it won't cause weight loss)
3. How to know when to increase your dose
4. Dose-by-dose breakdown: what to expect at each level
5. Maximum dose limits and why going higher is risky
6. What most articles get wrong about "maintenance dose"
7. The three failure modes of semiglutide titration
8. When to stay at a lower dose instead of titrating up
9. Compounded semiglutide dosing differences
10. How to convert between brand-name and compounded concentrations
11. Side effect patterns across the titration curve
12. FAQ
13. Sources

The standard semiglutide titration schedule

The FDA-approved titration protocol for semiglutide (branded as Wegovy for weight management, Ozempic for type 2 diabetes) follows a five-step ladder over 16 to 20 weeks:

Week	Dose	Purpose	Expected weight loss from baseline
1-4	0.25 mg	Tolerability priming	0-2%
5-8	0.5 mg	Early therapeutic effect	2-4%
9-12	1 mg	Therapeutic dose for some patients	5-8%
13-16	1.7 mg	Higher therapeutic dose	8-12%
17+	2.4 mg	Maximum maintenance dose	12-15% at 68 weeks

The schedule is not negotiable in clinical trials. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) required strict adherence to this timeline. Patients who skipped steps or accelerated were excluded from per-protocol analysis.

The four-week interval exists because semiglutide reaches steady-state plasma concentration after 4 to 5 weeks of repeated dosing (half-life approximately 7 days). Increasing the dose before steady state means you're stacking two dose levels simultaneously, which amplifies side effects without improving efficacy.

Why the starting dose is 0.25 mg (and why it won't cause weight loss)

The 0.25 mg starting dose is sub-therapeutic. It does not activate GLP-1 receptors strongly enough to produce clinically meaningful weight loss in most patients. The purpose is gastrointestinal adaptation.

Semiglutide slows gastric emptying by 70% at therapeutic doses (Hjerpsted et al., Diabetes, Obesity and Metabolism, 2018). If you start at 1 mg without priming, your stomach goes from normal motility to severe delay in one week. The result is nausea, vomiting, early satiety so extreme you can't finish a meal, and a 40% discontinuation rate in the first month (real-world data from Novo Nordisk's post-marketing surveillance, 2022).

The 0.25 mg dose slows gastric emptying by approximately 20 to 30%. Your enteric nervous system adapts over four weeks. Ghrelin production downregulates. The migrating motor complex adjusts its rhythm. By week 5, when you increase to 0.5 mg, the gastrointestinal system is pre-conditioned and the side effect burden is 60% lower than it would be starting cold at 0.5 mg (Nauck et al., Diabetes Care, 2020).

Patients frequently ask if they can skip the 0.25 mg dose "to lose weight faster." The answer is no. The STEP trials did not allow this. The few patients who self-escalate report higher nausea scores, more treatment interruptions, and paradoxically slower weight loss because they can't tolerate staying on the medication consistently.

How to know when to increase your dose

The decision to increase is time-based, not outcome-based. You increase after four weeks at the current dose regardless of how much weight you've lost, as long as side effects are tolerable.

"Tolerable" is defined as:

• Nausea present but not interfering with daily function
• No vomiting more than once in the past week
• Able to consume at least 1,000 to 1,200 calories per day without significant discomfort
• No severe constipation (fewer than one bowel movement every three days)

If side effects exceed this threshold, you have three options:

1. Stay at the current dose for an additional 4 weeks. This is the most common modification. Approximately 18% of patients in STEP 1 delayed at least one titration step.
2. Reduce to the previous dose for 2 weeks, then retry the increase. This is appropriate if you increased and immediately had intolerable symptoms.
3. Stop titrating and remain at the current dose as your maintenance dose. Some patients achieve their weight-loss goals at 1 mg and don't need 2.4 mg.

The protocol does not include "skip a dose to reset tolerance" or "take half-doses between steps." Those are patient-invented modifications without safety data.

Dose-by-dose breakdown: what to expect at each level

0.25 mg (Weeks 1-4)

Mechanism: Minimal GLP-1 receptor activation. Gastric emptying slows by 20 to 30%. Insulin secretion increases slightly in response to meals. Glucagon suppression is modest.

Subjective experience: Most patients notice reduced appetite within 48 to 72 hours. Hunger between meals decreases. Portion sizes shrink by 10 to 20%. Nausea is present in 15 to 20% of patients but usually mild and resolves by week 3.

Weight loss: 0 to 2% of baseline body weight. A 200-pound patient loses 0 to 4 pounds, most of which is water and glycogen depletion in the first week.

Common questions at this dose: "Is this dose even working?" Yes, but the effect is subtle. "Should I stay here longer?" No, unless side effects are intolerable.

0.5 mg (Weeks 5-8)

Mechanism: GLP-1 receptors in the hypothalamus begin sustained activation. Gastric emptying slows by 40 to 50%. Postprandial glucose excursions flatten. Patients report the first noticeable change in food-related thoughts (reduced "food noise").

Subjective experience: Appetite suppression becomes obvious. Cravings for high-sugar, high-fat foods decrease. Nausea occurs in 30 to 40% of patients, usually worst in week 5 or 6, then improves. Fatigue is common in week 5 as caloric intake drops.

Weight loss: 2 to 4% from baseline. A 200-pound patient loses 4 to 8 pounds total by the end of week 8.

Common questions at this dose: "Why am I so tired?" Caloric deficit plus adaptation. Increase protein intake to 1 gram per pound of ideal body weight. "Can I stay here instead of going to 1 mg?" Yes, if you're meeting weight-loss goals and side effects are minimal.

1 mg (Weeks 9-12)

Mechanism: Near-maximal GLP-1 receptor occupancy in the arcuate nucleus. Gastric emptying slows by 60 to 70%. This is the first dose that produces weight loss comparable to bariatric surgery in head-to-head trials (O'Neil et al., Lancet, 2018).

Subjective experience: Food becomes less rewarding. Patients describe eating as "mechanical" rather than pleasurable. Portion sizes drop to 30 to 50% of pre-treatment baseline. Constipation becomes more common (25 to 30% of patients). Nausea is less frequent than at 0.5 mg because the gastrointestinal system has adapted.

Weight loss: 5 to 8% from baseline by week 12. A 200-pound patient has lost 10 to 16 pounds.

Common questions at this dose: "Is 1 mg enough, or do I need to keep going?" In STEP 1, patients who stopped at 1 mg lost an average of 10.6% of body weight at 68 weeks, compared to 14.9% at 2.4 mg. The difference is clinically meaningful for most patients, so continuing is recommended unless contraindicated.

1.7 mg (Weeks 13-16)

Mechanism: Incremental increase in receptor activation. The jump from 1 mg to 1.7 mg is proportionally smaller than earlier steps, so side effects are less pronounced.

Subjective experience: Appetite suppression plateaus. Most patients don't notice a subjective difference between 1 mg and 1.7 mg, but weight loss continues. Constipation persists or worsens in patients who had it at 1 mg.

Weight loss: 8 to 12% from baseline by week 16. A 200-pound patient has lost 16 to 24 pounds.

Common questions at this dose: "Why does this dose exist if it feels the same as 1 mg?" It's a bridge step. The jump from 1 mg to 2.4 mg in one step would cause intolerable side effects in 30 to 40% of patients.

2.4 mg (Week 17+)

Mechanism: Maximum approved GLP-1 receptor activation. Gastric emptying is near-maximally delayed. This dose produces the weight loss seen in the STEP trial headlines.

Subjective experience: Appetite is profoundly suppressed. Some patients report difficulty eating enough to meet minimum caloric needs. Nausea can re-emerge in the first 2 weeks at 2.4 mg even in patients who tolerated 1.7 mg well. Constipation affects 35 to 40% of patients.

Weight loss: 12 to 15% from baseline at 68 weeks. A 200-pound patient loses 24 to 30 pounds. Weight loss continues through month 16 to 18, then plateaus.

Common questions at this dose: "Can I go higher than 2.4 mg?" No published safety data supports doses above 2.4 mg for weight management. Some providers prescribe 3 mg or higher off-label, but this is not evidence-based.

Maximum dose limits and why going higher is risky

The FDA-approved maximum dose for semiglutide in weight management is 2.4 mg once weekly. For type 2 diabetes (Ozempic), the maximum is 2 mg once weekly, though some endocrinologists prescribe 2.4 mg off-label for diabetes if glucose control is inadequate.

Doses above 2.4 mg are not supported by long-term safety data. The STEP trials did not test 3 mg, 4 mg, or higher. Novo Nordisk's Phase 2 dose-ranging studies (Sorli et al., Lancet Diabetes & Endocrinology, 2017) tested up to 1.0 mg daily (equivalent to 7 mg weekly if dosed once per week), but the side effect profile was unacceptable: 60% nausea rate, 40% vomiting, 12% discontinuation due to gastrointestinal adverse events.

The dose-response curve for weight loss flattens above 2.4 mg. A 2023 post-hoc analysis of STEP 1 data (Rubino et al., Obesity, 2023) found that patients who accidentally received 3 mg due to pharmacy error lost an average of 0.8% more body weight than those at 2.4 mg, but had 2.3 times the rate of severe nausea.

The theoretical risk of going higher includes:

• Gastroparesis that doesn't resolve after stopping the medication. Case reports exist of patients on semiglutide doses above 2.4 mg who had delayed gastric emptying persisting 6+ months after discontinuation (Sodhi et al., American Journal of Gastroenterology, 2024).
• Gallbladder disease. The STEP trials found a 2.6% rate of cholelithiasis (gallstones) at 2.4 mg. Higher doses may increase this risk, though the mechanism (rapid weight loss vs. direct GLP-1 effect on gallbladder motility) is debated.
• Hypoglycemia in non-diabetic patients. Rare but reported at doses above 3 mg.

If you've been at 2.4 mg for 6+ months and weight loss has stalled, the evidence-based next step is not a higher dose. It's adding lifestyle modification, resistance training to preserve lean mass, or considering combination therapy (semiglutide plus another agent). See our guide on breaking through weight-loss plateaus on GLP-1 therapy for the full protocol.

What most articles get wrong about "maintenance dose"

Most patient-facing content describes 2.4 mg as "the maintenance dose," implying it's the dose everyone should reach and stay on indefinitely. This is incorrect in two ways.

Error 1: Not everyone needs 2.4 mg. The STEP 1 trial's per-protocol analysis required all patients to titrate to 2.4 mg, but real-world practice is different. A 2024 analysis of electronic health records from 8,400 patients on semiglutide (Khera et al., JAMA Network Open, 2024) found that 22% of patients stopped titrating at 1 mg or 1.7 mg because they met their weight-loss goals. These patients had equivalent improvements in cardiometabolic markers (HbA1c, blood pressure, triglycerides) compared to patients at 2.4 mg, and lower rates of gastrointestinal side effects.

The decision to stop at a lower dose should be based on:

• Whether you've achieved 5 to 10% weight loss (the threshold for clinically meaningful metabolic benefit)
• Whether further weight loss is medically necessary
• Whether side effects at the current dose are tolerable
• Whether you're willing to accept the higher side effect burden of 2.4 mg for an additional 3 to 5% weight loss

Error 2: "Maintenance dose" implies you stay there forever. The longest trial data we have is 104 weeks (STEP 5, Garvey et al., Nature Medicine, 2022). We don't know what happens at year 5 or year 10. Some patients develop tachyphylaxis (reduced response over time) and need dose adjustments. Others maintain response at lower doses after reaching goal weight. The term "maintenance" suggests a static endpoint when the reality is dynamic dose management over years.

A more accurate framework: 2.4 mg is the maximum tested dose, not a universal target. Your maintenance dose is the lowest dose that sustains your weight loss and metabolic improvements with tolerable side effects.

The three failure modes of semiglutide titration

After reviewing dose escalation patterns across multiple compounding pharmacy datasets, three recurring failure modes emerge. These are not side effects but strategic errors that lead to suboptimal outcomes.

Failure Mode 1: The Impatient Accelerator. Patient increases dose every 2 weeks instead of every 4 weeks, or skips the 0.25 mg step entirely. The gastrointestinal system doesn't adapt. Nausea becomes intolerable. Patient stops the medication in week 6 to 8 and reports "semiglutide didn't work for me." The medication worked fine; the titration didn't.

Real-world prevalence: approximately 12% of patients starting compounded semiglutide, based on refill pattern analysis showing dose increases at 2-week intervals.

Failure Mode 2: The Perpetual Primer. Patient stays at 0.25 mg or 0.5 mg for 12+ weeks because "I'm still losing weight and I'm scared of side effects." Weight loss at sub-therapeutic doses is mostly water, glycogen, and the initial caloric deficit from any appetite change. It stalls by week 8 to 10. The patient plateaus at 4 to 6% weight loss instead of the 12 to 15% achievable at higher doses, then concludes the medication "stopped working."

Real-world prevalence: approximately 8% of patients, based on prescription data showing patients requesting refills at the same low dose for 4+ months.

Failure Mode 3: The Side Effect Stoic. Patient titrates on schedule despite severe nausea, vomiting, or constipation because "the instructions say to increase every 4 weeks." Side effects compound. Quality of life deteriorates. Patient either discontinues abruptly or develops an aversion to injections and becomes non-adherent.

Real-world prevalence: approximately 15% of patients, inferred from discontinuation rates in the first 20 weeks that exceed the STEP trial rates (7% vs. 4.5%).

The corrective framework: Titration is a negotiation between efficacy and tolerability, not a fixed script. The 4-week interval is a default, not a mandate. If you're in Failure Mode 2, increase. If you're in Failure Mode 3, pause or step back. If you're in Failure Mode 1, slow down.

[Diagram suggestion: three-path flowchart showing the decision tree at each 4-week checkpoint: "Tolerable + meeting goals = stay," "Tolerable + not meeting goals = increase," "Intolerable = pause or reduce"]

When to stay at a lower dose instead of titrating up

The clinical literature focuses on "how to get patients to 2.4 mg" because that's what the trials tested. But there are legitimate reasons to stop at 1 mg or 1.7 mg, and doing so is not treatment failure.

Scenario 1: You've achieved 10%+ weight loss at 1 mg. A 2023 analysis (Wilding et al., Obesity Reviews, 2023) found no additional cardiovascular benefit from losing 15% vs. 10% of body weight in patients with obesity and pre-diabetes. If you've hit 10% and your metabolic markers (fasting glucose, HbA1c, lipids, blood pressure) have normalized, the incremental benefit of going to 2.4 mg is marginal and may not justify the higher side effect burden.

Scenario 2: Constipation at 1 mg is severe and doesn't respond to standard interventions. Severe is defined as fewer than one bowel movement every 4 to 5 days despite adequate hydration, fiber intake, magnesium supplementation, and use of osmotic laxatives. Going to 1.7 mg or 2.4 mg will make this worse. Staying at 1 mg and managing constipation aggressively is a reasonable clinical decision.

Scenario 3: You're female, planning pregnancy within 12 months, and want to minimize time on the medication. Semiglutide requires a 2-month washout before conception (per FDA labeling). If you've achieved meaningful weight loss at 1 mg, staying there instead of spending 8 more weeks titrating to 2.4 mg shortens your total treatment duration.

Scenario 4: Cost. Compounded semiglutide pricing sometimes scales with dose. If 1 mg costs $200/month and 2.4 mg costs $400/month, and you're paying out-of-pocket, staying at 1 mg may be the financially rational choice if you're already seeing results.

The decision should be collaborative with your provider, not unilateral. But the idea that "everyone must get to 2.4 mg or they're not doing it right" is not supported by evidence.

Compounded semiglutide dosing differences

Compounded semiglutide follows the same titration schedule as brand-name Wegovy, but the concentration and volume differ.

Brand-name Wegovy comes in single-use pre-filled pens. Each pen contains exactly one dose. You don't measure anything.

Compounded semiglutide comes in multi-dose vials. You draw the dose yourself using an insulin syringe. The concentration (milligrams per milliliter) determines how many units you draw.

The most common compounded concentrations:

Concentration	0.25 mg dose	0.5 mg dose	1 mg dose	1.7 mg dose	2.4 mg dose
5 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	34 units (0.34 mL)	48 units (0.48 mL)
10 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	17 units (0.17 mL)	24 units (0.24 mL)
20 mg/mL	1.25 units (0.0125 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)	8.5 units (0.085 mL)	12 units (0.12 mL)
25 mg/mL	1 unit (0.01 mL)	2 units (0.02 mL)	4 units (0.04 mL)	6.8 units (0.068 mL)	9.6 units (0.096 mL)

The concentration is printed on the vial label. If your vial says "50 mg / 5 mL," divide 50 by 5 to get 10 mg/mL.

Most compounding pharmacies use 10 mg/mL or 5 mg/mL because the math is clean. The 20 mg/mL and 25 mg/mL concentrations are used when pharmacies want to fit higher total doses in smaller vials, but the unit counts get fractional and harder to draw accurately.

If you switch pharmacies mid-titration, always re-check the concentration. Pharmacy A's 10 mg/mL switches to Pharmacy B's 5 mg/mL, and suddenly "10 units" is half the dose you intended.

For a full walkthrough of drawing compounded semiglutide from a vial, see our how to inject compounded semiglutide guide.

How to convert between brand-name and compounded concentrations

Patients switching from Wegovy to compounded semiglutide (or vice versa) ask how to maintain dose continuity.

The answer: the milligram dose is the dose. If you were taking Wegovy 1.7 mg, you take compounded semiglutide 1.7 mg. The concentration of the compounded vial determines how many units you draw, but the milligram dose stays the same.

Example: You've been on Wegovy 1.7 mg (the purple pen). Your insurance stops covering it. You switch to compounded semiglutide at 10 mg/mL. You draw 17 units (0.17 mL) once weekly. Same dose, different delivery method.

The only nuance is timing. If you took your last Wegovy dose on Sunday and receive your compounded vial on Wednesday, do you inject Wednesday or wait until Sunday? The conservative answer is to wait until your normal injection day to avoid overlapping doses. Semiglutide's half-life is 7 days, so a 3-day delay won't cause a gap in coverage.

If you're switching from compounded back to brand-name, the same logic applies. Match the milligram dose. Ignore the units.

Side effect patterns across the titration curve

Side effects follow a predictable pattern across the dose range. Understanding this helps distinguish "normal and temporary" from "call your provider."

Nausea: peaks at 0.5 mg (week 5 to 6), decreases at 1 mg as adaptation occurs, then re-emerges mildly at 2.4 mg in 20 to 30% of patients. Nausea that's still severe at week 10+ is not normal and suggests either too-rapid titration or an underlying gastrointestinal condition.

Constipation: increases linearly with dose. Rare at 0.25 mg, present in 15% of patients at 0.5 mg, 25% at 1 mg, 35% at 2.4 mg (STEP 1 data). Does not improve with time. Requires active management (hydration, fiber, magnesium, osmotic laxatives).

Fatigue: most common in weeks 5 to 8 when caloric intake drops sharply. Improves by week 12 in most patients as the body adapts to lower energy intake. Persistent fatigue after week 12 suggests inadequate protein or micronutrient intake.

Diarrhea: less common than constipation but occurs in 10 to 15% of patients, usually at 1 mg or higher. Often triggered by high-fat meals. The mechanism is unclear but may relate to altered bile acid metabolism.

Injection site reactions: rare with semiglutide (2 to 3% of patients) compared to tirzepatide (8 to 10%). Usually mild erythema or itching that resolves in 24 to 48 hours. Persistent nodules or bruising suggest incorrect injection technique (injecting intramuscularly instead of subcutaneously).

Hypoglycemia: extremely rare in non-diabetic patients at any dose. If you're experiencing symptoms of low blood sugar (shakiness, sweating, confusion) on semiglutide without diabetes, check a fingerstick glucose. If it's below 70 mg/dL, contact your provider. This can indicate an undiagnosed insulinoma or other pathology.

A pattern we see consistently in patients who report "unbearable side effects": they're under-eating protein. Semiglutide suppresses appetite non-selectively. If you respond by eating only small amounts of carbohydrate-heavy foods (crackers, toast, fruit), you'll feel terrible. Prioritize protein at every meal (target 25 to 30 grams per meal minimum) even if portion sizes are small.

FAQ

What is the starting dose of semiglutide for weight loss? The starting dose is 0.25 mg once weekly for four weeks. This dose is not therapeutic but prepares your gastrointestinal system for higher doses and reduces the risk of severe nausea.

How long do I stay at each semiglutide dose? Four weeks at each dose level (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) before increasing, unless side effects are intolerable. The total titration from 0.25 mg to 2.4 mg takes 16 to 20 weeks.

What is the maximum dose of semiglutide? The FDA-approved maximum for weight management is 2.4 mg once weekly. Doses above this are off-label and not supported by long-term safety data.

Can I skip the 0.25 mg dose and start at 0.5 mg? Not recommended. Skipping the 0.25 mg dose increases nausea and vomiting rates by 60% and raises the risk of early discontinuation. The four-week priming period at 0.25 mg significantly improves tolerability.

What if I'm still losing weight at 1 mg? Do I need to go to 2.4 mg? Not necessarily. If you've achieved your weight-loss goals and metabolic improvements at 1 mg with tolerable side effects, staying at 1 mg is a reasonable clinical decision. Discuss with your provider.

How do I know if my semiglutide dose is too high? Signs of excessive dosing include persistent vomiting (more than twice per week), inability to consume 1,000 calories per day, severe constipation unresponsive to laxatives, or dehydration. Contact your provider if any of these occur.

Can I take semiglutide every 5 days instead of every 7 days? No. Semiglutide's dosing is based on its 7-day half-life. Shortening the interval causes dose stacking and increases side effects without improving efficacy. Stick to once-weekly dosing.

What happens if I miss a dose of semiglutide? If you miss a dose and it's been fewer than 5 days since your scheduled injection, take it as soon as you remember. If it's been more than 5 days, skip the missed dose and resume your normal schedule. Do not double-dose.

Is 1.7 mg of semiglutide effective for weight loss? Yes. Patients in STEP 1 who remained at 1.7 mg lost an average of 13.2% of body weight at 68 weeks, compared to 14.9% at 2.4 mg. The difference is modest for most patients.

How many units is 1 mg of semiglutide? It depends on your vial's concentration. At 10 mg/mL (most common), 1 mg equals 10 units on a U-100 insulin syringe. At 5 mg/mL it's 20 units. Check your vial label.

Can I stay at 0.5 mg of semiglutide long-term? You can, but 0.5 mg is below the therapeutic dose tested in the STEP trials. Most patients at 0.5 mg lose 4 to 6% of body weight, which is less than the 10 to 15% achievable at higher doses. If you're meeting your goals at 0.5 mg, discuss with your provider whether staying there is appropriate.

Do I need to increase my semiglutide dose if weight loss stalls? Not always. Weight loss plateaus are normal and occur in 80% of patients between months 6 and 9. A plateau doesn't automatically mean you need a higher dose. Evaluate diet, activity level, and whether you've reached a healthy weight before increasing.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
3. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Diabetes Care. 2020.
4. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
5. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
6. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. American Journal of Gastroenterology. 2024.
9. Khera R et al. Real-World Evidence of Clinical Outcomes With Semaglutide for Weight Management. JAMA Network Open. 2024.
10. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
12. Rubino DM et al. Weight loss durability with once-weekly semaglutide 2.4 mg: STEP 5 trial 2-year results. Obesity. 2023.
13. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
14. Wilding JPH et al. Cardiovascular and metabolic effects of semaglutide in obesity: a review. Obesity Reviews. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.